A case-control study of therapy of amifostine plus chemotherapy on acute myeloid leukemia consolidation
10.3760/cma.j.issn.1008-6315.2013.12.015
- VernacularTitle:化疗联合阿米福汀在急性髓性白血病中的病例对照研究
- Author:
Jin LU
;
Shen ZHANG
;
Hao JIANG
;
Bin JIANG
;
Xiaojun HUANG
- Publication Type:Journal Article
- Keywords:
Acute myeloid leukemia;
Amifostine
- From:
Clinical Medicine of China
2013;29(12):1278-1281
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the protective effect of normal hematopoietic and without causing the increase of relapse rate of amifostine in patients with acute myeloid chemotherapy.Methods One hundred and forty-two acute myeloid leukemia(AML) patients were selected and divided into combination group(n =56) and chemotherapy alone group (n =86).Hematological toxicity and non-hematologic toxicity,response rate,duration of response of patients were prospective,non-randomized,case-control study.Results Fifty-six patients in combined group included 30 male and 26 female patients,and 18 patients in high risk stage and 32 patients in intermediate risk stage and 6 patients in low risk.The median age was (35.14 ± 14.42) year in combination group.Chemotherapy alone group included 58 male 28 female patients,and 14 patients in high risk and 64 patients in intermediate risk and 8 patients in low risk.The median age was (46.58 ± 16.99) year.There were no significant difference between two groups in terms of gender (P =0.318) and risk stage(P =0.262).But more young patients were in combination group compared with chemotherapy alone group and there was significant difference(P =0.004).In combination group,42.9％ (24 cases)patients got high Ara-C dose and 32.1％ (18 cases) patients got high HAA dose chemotherapy compared with control group (14.9％ (12 cases)and 20.9％ (18 cases)).The during periods of platelet with ＜20 × 109/L in combination was 0(0,7) day,lower than that in chemotherapy alone group (9 (4,14),P =0.01).Meanwhile the volume of platelet infusion in combination group was less than that in chemotherapy alone group and the nadir of platelet4(0(0,3) U vs.4(1,6) U,P =0.02).No statistic difference was found in two groups regarding of non-hematological side effects and the relapse rate (before and after treatment,combination group:96.4％ (54/56) ; Chemotherapy alone group:98.8 ％ (85/86) ; P=0.062).Conclusion Amifostine may provide protection for AML patients,can short duration of thrombocytopenia,reduce platelet transfusions,and other side effect was no significant difference.
